CagriSema Phase 3 trial investigates optimal lower doses for weight loss in overweight and obese adults
Background
The global epidemic of obesity presents significant health challenges, increasing risks for type 2 diabetes, cardiovascular disease, and other comorbidities. Current pharmacological interventions often achieve modest weight loss or come with undesirable side effects, highlighting a critical need for more effective and tolerable treatments. CagriSema, a fixed-dose combination of semaglutide (a GLP-1 receptor agonist) and cagrilintide (an amylin analog), is being developed to leverage synergistic mechanisms. While semaglutide reduces appetite and food intake, cagrilintide further enhances satiety and slows gastric emptying, offering a potent dual-action approach to weight management. Previous studies with higher doses of CagriSema have shown substantial weight reductions, prompting investigation into lower, potentially equally efficacious and better-tolerated doses.
Study Design
This Phase 3, randomized, quadruple-blind, placebo-controlled trial enrolled 300 participants with overweight or obesity to assess the efficacy and safety of lower CagriSema doses. Participants were randomized to receive once-weekly subcutaneous injections of either CagriSema 1.0 mg/1.0 mg, CagriSema 1.7 mg/1.7 mg, or a matched placebo. The study duration is 68 weeks, with the primary endpoint focusing on the percentage change in body weight from baseline. Secondary endpoints include the proportion of participants achieving specific weight loss thresholds (e.g., ≥5%, ≥10%, ≥15%), changes in BMI, and safety and tolerability profiles. The quadruple-blind design ensures that participants, investigators, site staff, and the sponsor remain unaware of treatment assignments, minimizing bias.
Results
As of the current record, this Phase 3 trial (NCT06388187) is listed as 'COMPLETED' but has a future completion date of April 22, 2026. Therefore, the detailed efficacy and safety results for CagriSema 1.0 mg/1.0 mg and 1.7 mg/1.7 mg in participants with overweight or obesity are not yet available. The study aims to quantify the magnitude of body weight reduction achieved with these specific lower doses compared to placebo and to thoroughly assess their safety and tolerability profiles. Previous research with a higher dose of CagriSema 2.4 mg/2.4 mg has demonstrated significant and clinically relevant body weight reductions, providing a strong rationale for investigating these potentially optimized lower dose combinations. The upcoming results are expected to detail the mean percentage body weight change, the proportion of responders achieving various weight loss thresholds, and the incidence of adverse events across the treatment arms.
Why It Matters
Optimizing CagriSema dosing could expand treatment options for obesity by identifying regimens that balance efficacy with improved tolerability, potentially leading to broader patient adoption and adherence. Finding effective lower doses, such as 1.0 mg/1.0 mg or 1.7 mg/1.7 mg, could reduce the incidence or severity of side effects commonly associated with GLP-1 agonists and amylin analogs, making long-term use more sustainable. This research is crucial for establishing a flexible dosing paradigm for CagriSema, allowing clinicians to tailor treatment to individual patient needs and responses. If these lower doses prove effective, they could offer a more accessible and potentially cost-effective option for managing obesity, moving closer to a usable protocol for a wider range of individuals seeking significant and sustained weight loss.